Suppr超能文献

经导管主动脉瓣植入术治疗重度主动脉瓣狭窄患者的无创心输出量测量不准确。

Noninvasive cardiac output measurements are inaccurate in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation.

机构信息

Department of Anesthesiology, Hitachi General Hospital, Hitachi, Japan.

Department of Anesthesiology, National Cerebral and Cardiovascular Center, Suita, Japan.

出版信息

Korean J Anesthesiol. 2022 Apr;75(2):151-159. doi: 10.4097/kja.21324. Epub 2021 Oct 20.

Abstract

BACKGROUND

Noninvasive cardiac output (CO) measured using ClearSight™ eliminates the need for intra-arterial catheter insertion. The purpose of this study was to examine the accuracy of non-invasive CO measurement in patients with severe aortic valve stenosis (AS).

METHODS

Twenty-eight patients undergoing elective transcatheter aortic valve implantation were prospectively enrolled in this study. The CO was simultaneously measured twice before and twice after valve deployment (total of four times) per patient, and the CO was compared between the ClearSight (COClearSight) system and the pulmonary artery catheter (PAC) thermodilution (COTD) method as a reference. The Bland-Altman analysis was used to compare the percentage errors between the methods.

RESULTS

A total of 112 paired data points were obtained. The percentage error between the COClearSight and COTD was 43.1%. The paired datasets were divided into the following groups according to the systemic vascular resistance index (SVRI): low (< 1,200 dyne s/cm5/m2) and normal (1,200-2,500 dyne s/cm5/m2). The percentage errors were 44.9% and 49.4%, respectively. The discrepancy of CO between COClearSight and COTD was not significantly correlated with SVRI (r = -0.06, P < 0.001). The polar plot analysis showed the trending ability of the COClearSight after artificial valve deployment was 51.1% which below the acceptable cut-off (92%).

CONCLUSIONS

The accuracy and the trending ability of the ClearSight CO measurements were not acceptable in patients with severe AS. Therefore, the ClearSight system is not interchangeable with the PAC thermodilution for determining CO in this population.

摘要

背景

使用 ClearSight™ 测量的无创心输出量 (CO) 无需插入动脉内导管。本研究的目的是检查非侵入性 CO 测量在严重主动脉瓣狭窄 (AS) 患者中的准确性。

方法

本研究前瞻性纳入 28 例接受择期经导管主动脉瓣植入术的患者。每位患者在瓣膜植入前和植入后各进行两次 CO 测量(共四次),并将 ClearSight(COClearSight)系统与肺动脉导管(PAC)热稀释法(COTD)的 CO 进行比较作为参考。采用 Bland-Altman 分析比较两种方法的百分比误差。

结果

共获得 112 对配对数据点。COClearSight 与 COTD 的百分比误差为 43.1%。根据全身血管阻力指数(SVRI)将配对数据集分为以下两组:低(<1200 迪恩·秒/厘米 5/米 2)和正常(1200-2500 迪恩·秒/厘米 5/米 2)。误差百分比分别为 44.9%和 49.4%。COClearSight 与 COTD 之间 CO 的差异与 SVRI 无显著相关性(r=-0.06,P<0.001)。极坐标图分析显示,人工瓣膜植入后 COClearSight 的趋势能力为 51.1%,低于可接受的截止值(92%)。

结论

在严重 AS 患者中,ClearSight CO 测量的准确性和趋势能力不可接受。因此,在该人群中,ClearSight 系统与 PAC 热稀释法不能互换用于确定 CO。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcd9/8980286/62a5ad9ad1ae/kja-21324f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验